Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

Business Wire September 7, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September

Business Wire September 6, 2022

Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Business Wire August 9, 2022

Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Business Wire July 26, 2022

Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer

Business Wire July 11, 2022

Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies

Business Wire July 7, 2022

Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference

Business Wire July 5, 2022

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

Business Wire June 21, 2022

Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

Business Wire June 16, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June

Business Wire May 31, 2022

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

Business Wire May 26, 2022

Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022

Business Wire May 26, 2022

Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update

Business Wire May 10, 2022

Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May

Business Wire May 4, 2022

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Business Wire May 3, 2022

Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022

Business Wire April 26, 2022

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

GlobeNewswire April 26, 2022

Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin's Lymphoma

Business Wire April 14, 2022

Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors

Business Wire April 13, 2022

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Business Wire March 25, 2022